Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999894 · ClinicalTrials.gov registry record · Phase 2
Open-label Study of Safety and Tolerability of Memantine in Children With Autism
A Phase 2 study of Autism and Pediatric Autism, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 19
- Study locations
NCT01999894: Completed Phase 2 study of Autism and Pediatric Autism, sponsored by Forest Laboratories.
NCT01999894 is a Phase 2 study of Autism and Pediatric Autism that has completed, run by Forest Laboratories. The registered enrollment target is 102 participants, below the 182-participant average among 104 other Autism trials with a reported enrollment target (44% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01999894, a Phase 2 study of Autism and Pediatric Autism, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.
Primary Outcome
Number of patients who experienced one or more TEAEs during the study
Conditions Studied
Interventions
- DRUG Memantine HCl
Study Locations (19)
California
- Forest Investigative Site 003 - Sacramento
- Forest Investigative Site 021 - San Francisco
- Forest Investigative Site 026 - Santa Ana
- Forest Investigative Site 020 - Santa Ana
- Forest Investigative Site 002 - Stanford
Ohio
- Forest Investigative Site 013 - Cleveland
- Forest Investigative Site 015 - Cleveland
- Forest Investigative Site 001 - Columbus
Florida
- Forest Investigative Site 024 - Jacksonville Beach
- Forest Investigative Site 007 - St. Petersburg
Illinois
- Forest Investigative Site 014 - Hoffman Estates
- Forest Investigative Site 023 - Naperville
New Jersey
- Forest Investigative Site 011 - Toms River
- Forest Investigative Site 006 - Voorhees Township
Arizona
- Forest Investigative Site 005 - Phoenix
Indiana
- Forest Investigative Site 010 - Indianapolis
Massachusetts
- Forest Investigative Site 025 - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
What the finished NCT01999894 record still lists
NCT01999894 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 182-participant average among 104 other Autism trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Autism appearing as the primary indexed condition, and to 1 intervention - of which Memantine HCl is the first listed.
NCT01999894 lists 19 locations in 10 states (California, Ohio, Florida).
Frequently Asked Questions
What is clinical trial NCT01999894 about?
NCT01999894 is a clinical study titled "Open-label Study of Safety and Tolerability of Memantine in Children With Autism". The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.
What is the current status of trial NCT01999894?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2009-11. Estimated completion is 2013-02.
What conditions does trial NCT01999894 study?
This clinical trial studies the following conditions: Autism, Pediatric Autism.
What interventions are being tested in trial NCT01999894?
The interventions under investigation include: Memantine HCl (DRUG).
Who is sponsoring clinical trial NCT01999894?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01999894 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01999894's enrollment target sits among peer trials
102 37th of 104 higher than 68 of 104 other Autism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
The Impact of a Virtual Magic Trick Training Program
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
A Study of Esomeprazole in Children With Autism
RECRUITING · Phase 2
-
Trial of Diphenhydramine for Sleep in Children With Autism
RECRUITING · Phase 2
-
Trial of Suvorexant for Sleep in Children With Autism
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia